Wang Yan, Liu Xin-Yong, De Clercq Erik
Department of Medicinal Chemistry, School of Pharmaceutical Sciences, Shandong University, No.44 Wenhuaxi Road, Jinan 250012 , China.
Mini Rev Med Chem. 2009 Mar;9(3):379-85. doi: 10.2174/1389557510909030379.
Transcription is considered to be a crucial step in the replication cycle of HIV-1. Tat regulates an early step of transcription elongation. The positive elongation factor P-TEFb, a heterodimer containing a catalytic subunit (CDK9) and unique regulatory cyclins (CycT1), is required for HIV-1 Tat transcriptional activation. This is a potential target for new HIV-1 transcription inhibitors. Without P-TEFb, transactivation is restrained and only short transcripts are generated. All the P-TEFb inhibitors can suppress the HIV-1 transactivation process by inhibition of CycT1, CDK9 or their interaction. Several low-molecular-weight compounds such as flavopiridol, roscovitine and the human small nuclear RNA 7SK which have been showed to possess potent anti-HIV activity by interfering with P-TEFb functions are reviewed in this article.
转录被认为是HIV-1复制周期中的关键步骤。Tat调节转录延伸的早期步骤。正性延伸因子P-TEFb是一种异二聚体,包含一个催化亚基(CDK9)和独特的调节细胞周期蛋白(CycT1),是HIV-1 Tat转录激活所必需的。这是新型HIV-1转录抑制剂的一个潜在靶点。没有P-TEFb,反式激活受到抑制,仅产生短转录本。所有P-TEFb抑制剂都可以通过抑制CycT1、CDK9或它们的相互作用来抑制HIV-1反式激活过程。本文综述了几种低分子量化合物,如黄酮哌啶醇、罗司维汀和人小核RNA 7SK,它们已被证明通过干扰P-TEFb功能而具有强大的抗HIV活性。